Genotypic analysis of primary and metastatic cutaneous melanoma

Cancer Genetics and Cytogenetics

Volumn 140, Issue 1, 2003, Pages 37-44

  Rao, U N M ^a   Jones, M W ^b   Finkelstein, S D ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ALLELIC IMBALANCE; ARTICLE; CANCER INVASION; CHROMOSOME 10Q; CHROMOSOME 1P; CHROMOSOME 5Q; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DISSECTION; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MARKER GENE; MELANOMA; METASTASIS; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN CARCINOMA; TUMOR VOLUME;

ALLELES; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; CLONE CELLS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DELETION; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MALE; MELANOMA; MICROSATELLITE REPEATS; NEOPLASM INVASIVENESS; NEVUS, PIGMENTED; SKIN NEOPLASMS; VULVAR NEOPLASMS;

EID: 0037241718     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00651-9     Document Type: Article

References (50)

1. Edwards S.L., Blessing K. Problematic pigmented lesions. approach to diagnosis J Clin Pathol. 53:2000;409-418.
2. Grant-Kels J.M., Bason E.T., Grin C.M. The misdiagnosis of malignant melanoma. J Am Acad Dermatol. 40:1999;539-548.
3. Barnhill R. Malignant melanoma, dysplastic nevi and Spitz tumors. Histologic classification and characteristics. Clin Plast Surg. 27:2000;331-360.
4. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., Urist M., McMasters K.M., Ross M.I., Kirkwood J.M., Atkins M.B., Thompson J.A., Coit D.G., Byrd D., Desmond R., Zhang Y., Liu P.Y., Lyman G.H., Morabito A. Prognostic factors analysis of 17600 melanoma patients. validation of the American Joint Committee on Cancer Melanoma Staging J Clin Oncol. 19:2001;3622-3634.
5. Reed J.A., Albino A.P. Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Dermatol Clin. 17:1999;631-643.
6. Walker G.J., Palmer J.M., Walters M.K., Hayward N.K. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer. 12:1995;134-141.
7. Bastian B.C., LeBoit P.E., Hamm H., Broecker E.-B., Pinkel D. Chromosomal gains and losses in primary cutaneous melanoma detected by comparative genomic hybridization. Cancer Res. 58:1998;2170-2175.
8. Miele M.E., Jewett M.D., Goldberg S.F., Hyatt D.L., Morelli C., Gualandi F., Rimessi P., Hicks D.J., Weissman B.E., Barbanti-Brodano G., Welch D.R. A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int J Cancer. 86:2000;524-528.
9. Pollack P.M., Trent J.M. Genetics of cutaneous melanoma. Clin Lab Med. 4:2000;667-690.
10. Morita R., Fujimoto A., Hatta N., Takehara K., Takata M. Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol. 111:1998;919-924.
11. Takata M., Morita R., Takehara K. Clonal heterogeneity in sporadic melanomas as revealed by loss of heterozygosity analysis. Int J Cancer. 85:2000;492-497.
12. Mertens F., Johansson B., Hoglund M., Mite lman F. Chromosomal imbalance maps of malignant solid tumors. a cytogenetic survey of 3185 neoplasms Cancer Res. 57:1997;2765-2780.
13. Hoglund M., Gisselsson D., Mandahl N., Johansson B., Mertens F., Mitelman F., Sall T. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution. Genes Chromosomes Cancer. 31:2001;156-171.
14. Talwalkar V.R., Scheiner M., Hedges L.K., Butler M.G., Schwartz H.S. Microsatellite instability in malignant melanoma. Cancer Genet Cytogenet. 15:1998;111-114.
15. Hussein M.R., Roggero E., Sudilovsky E.C., Tuthill R.J., Wood G.S., Sudilovsky O. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol. 23:2001;308-314.
16. Piepkorn M. Melanoma genetics. an update with focus on the CDKN2A(p16)/ARF tumor suppressors J Am Acad Dermatol. 42:2000;705-722.
17. Platz A., Ringborg U., Hansson J. Heriditary cutaneous melanoma. Semin Cancer Biol. 10:2000;319-326.
18. Palmieri G., Cossu A. Definition of role of 9p21 in sporadic melanoma. Br J Cancer. 83:2000;1707-1714.
19. Park W.S., Vortmeyer A.O., Pack S., Duray P.H., Boni R., Guerami A.A., Emmert-Buck M.R., Liotta L.A., Zhuang Z. Allelic deletion at chromosome 9p21 (p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol. 29:1998;127-130.
20. Boni R., Zhuang Z., Albuquerque A., Vortmeyer A., Duray P. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. Arch Dermatol. 134:1998;882-883.
21. Healy E., Belgaid C.E., Takata M., Vahlquist A., Rehman I., Rigby H., Rees J.L. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 56:1996;589-593.
22. Smedley D., Sidhar S., Birdsall S., Bennett D., Herlyn M., Cooper C., Shipley J. Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer. 28:2000;121-125.
23. Greene M.H. The genetics of hereditary melanoma and nevi, 1998 update. Cancer. 86(Suppl 112464-77.):1999;. [review].
24. Goldstein A.M., Dracopoli N.C., Ho E.C., Fraser M.C., Kearns K.S., Bale S.J., McBride O.W., Clark W.H., Tucker M.A. Further evidence for a locus for cutaneous malignant melanoma - dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet. 52:1993;537-550.
25. Boni R., Matt D., Voetmeyer A., Burg G., Zhuang Z. Chromosomal allele loss in primary cutaneous melanoma is heterogeneous and correlates with proliferation. J Invest Dermatol. 110:1998;215-217.
26. Greene M.H. Genetics of cutaneous melanoma and nevi. Mayo Clin Proc. 72:1997;467-474.
27. Indsto J.O., Holland E.A., Kefford R.F., Mann G.J. 10q deletions in metastatic cutaneous melanoma. Cancer Genet Cytogenet. 100:1998;68-71.
28. Teng D.H.F., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K.L., Vinson V.L., Gumpper K.L., Ellis L., El-Naggar A., Frazier M., Jasser S., Langford L.A., Lee J., Mills G.B., Pershouse M.A., Pollack R.E., Tornos C., Troncoso P., Yung W.K.A., Fujii G., Berson A., Bookstein R., Bolen J.B., Tavtigian S.V., Steck P.A. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57:1997;5221-5235.
29. Guldberg P., Straten P.T., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57:1997;3660-3663.
30. Reifenerger J, Wolter M, Bostrom J, Buschger R, Shultz KW, Meahead H, Ruziky T, Reijenberger G. Allelic losses on chromosome arm 10q and mutation of PTEN/MMAC1. Virchow's Arch 2000;487-93.
31. Robertson G.P., Furnari F.B., Miele M.E., Glendening M.J., Welch D.R., Fountain J.W., Lugo T.G., Huang H.J.S., Cavenee W.K. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA. 95:1998;9418-9423.
32. Robertson G.P., Herbst R.A., Nagane M., Huang H.J.S., Cavenee W.K. The chromosome 10 monosomy common in human melanoma results from the loss of two separate tumor suppressor loci. Cancer Res. 59:1999;3596-3601.
33. Whiteman D.C., Parsons P.G., Green A.C. P53 expression and risk factors for cutaneous melanoma. a case control study Int J Cancer. 77:1998;843-848.
34. Platz A., Ringborg U., Grafstrom E., Hoog A., Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma. increased immunopositivity in hereditary melanoma Melanoma Res. 5:1995;101-106.
35. Kaleem Z., Lind A.C., Humphrey P.A., Sueper R.H., Swanson P.E., Ritter J.H., Wick M.R. Concurrent ki67 and p53 immunolabeling in melanoma. Modern Pathol. 13:2000;217-222.
36. Birindelli S., Tragni G., Bartoli C., Ranzani G.N., Rilke F., Pierotti M.A., Pilotti S. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer. 86:2000;255-261.
37. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C., Lueders J., Glatfelter A., Pollock P., Carpten J., Gillanders E., Leja D., Dietrich K., Beaudry C., Berens M., Alberts V., Sondak V., Hayward N., Trent J. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 406:2000;536-540.
38. Finkelstein S.D., Hasegawa T., Colby T., Yousem S.A. 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol. 155:1999;633-640.
39. Finkelstein S.D., Przygodzki R., Swalsky P.A. Microdissection-based p53 genotyping. concepts for molecular testing Mol Diagnosis. 3:1998;179-191.
40. Finkelstein S.D., Przygodzki R.M., Pricolo V.E., Sakallah S.A., Swalsky P.A., Bakker A., Lanning R., Bland K.I., Cooper D.L. Prediction of biological aggressiveness in colorectal cancer by p53/k-ras-2 topographic genotyping. Mol Diagnosis. 1:1996;5-28.
41. Rao U.N., Bakker A., Swalsky P.A., Finkelstein S.D. Max interacting protein 1. loss of heterozygosity is frequent in desmoplastic melanoma Mod Pathol. 12:1999;344-350.
42. Bastian B.C., Wesselmann U., Pinkel D., LeBoit P.E. Molecular cytogenetic analysis of Spitz nevi shows clear differences in melanoma. J Invest Dermatol. 113:1999;1065-1069.
43. Healy E., Belgaid C., Takata M., Harrison D., Zhu N.W., Burd D.A.R., Rigby H.S., Matthews J.N.S., Rees J.L. Prognostic significance of allelic losses in primary melanoma. Oncogene. 16:1998;2213-2218.
44. Bogdan I., Burg G., Boni R. Spitz nevi display deletions. Arch Dermatol. 137:2001;1417-1420.
45. Bogdan I., Xin H., Berg G., Boni R. Heterogeneity of allelic deletions within melanoma metastases. Melanoma Res. 11:2001;349-354.
46. Herbst R.A., Podewski E.K., Mommert S., Kapp A., Weiss J. PTEN and MXI1 allelic loss on chromosome 10q is rare in melanoma in vivo. Arch Dermatol Res. 291:1999;567-569.
47. Poetsch M., Woenckhaus C., Dittberner T., Pamber M., Lorenz Z., Herrmann F.H. Differences in chromosomal aberrations between nodular and superficial spreading melanoma detected by interphase cytogenetics. Lab Invest. 78:1998;883-888.
48. Doneda L., Wiegant J., Larizza L. Three-way and two-way rearrangements involving chromosomes 10, 2, 5, 2 in two marker chromosomes of a human melanoma cell line. Melanoma Res. 4:1994;259-265.
49. Cree I.A. Cell cycle and melanoma-two different tumors from the same cell type. J Pathol. 191:2000;112-114. [editorial].
50. Jiveskog S., Ragnarsson-Olding B., Platz A., Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol. 111:1998;757-761.